34 results match your criteria Current Pharmacogenomics and Personalized Medicine[Journal]

  • Page 1 of 1

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review.

Curr Pharmacogenomics Person Med 2017 Dec;15(2):81-85

Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.

Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692115666170815161754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872368PMC
December 2017
3 Reads

Ethical, Political and Societal Implications of the Open Access Journal Movement in the Era of Economic Crisis, with Emphasis on Public Health Pharmacogenomics.

Curr Pharmacogenomics Person Med 2013 Dec;11(4):312-315

School of Public Health, Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.

Publication of the research outputs is a vital step of the research processes and a gateway between the laboratory and the global society. Open Access is revolutionizing the dissemination of scientific ideas, particularly in the field of public health pharmacogenomics that examines the ways in which pharmacogenomics impacts health systems and services at a societal level, rather than a narrow bench to bedside model of translation science. This manuscript argues that despite some limitations and drawbacks, open access has profound ethical, political and societal implications especially on underdeveloped and developing countries, and that it provides opportunities for science to grow in these resource-limited countries, particularly in the era of a severe economic and financial crisis that is imposing cuts and restrictions to research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692111666131126234122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101803PMC
December 2013
7 Reads

A Conceptual Model of Psychoneurological Symptom Cluster Variation in Women with Breast Cancer: Bringing Nursing Research to Personalized Medicine.

Curr Pharmacogenomics Person Med 2013 Sep;11(3):224-230

Virginia Commonwealth University School of Nursing.

Personalized medicine applies knowledge about the patient's individual characteristics in relation to health and intervention outcomes, including treatment response and adverse side-effects, to develop a tailored treatment plan. For women with breast cancer, personalized medicine has substantially improved the rate of survival, however, a high proportion of these women report multiple, co-occurring psychoneurological symptoms over the treatment trajectory that adversely affect their quality of life. In a subset of these women, co-occurring symptoms referred to as symptoms clusters, can persist long after treatment has ended. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909649PMC
September 2013
19 Reads

Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.

Curr Pharmacogenomics Person Med 2013 Mar;11(1):31-41

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA ; Winship Cancer Institute, Atlanta, GA, USA.

Acquired resistance to trastuzumab is a clinical problem in the treatment of HER2-over-expressing metastatic breast cancer. Importantly, an earlier report suggested that high body mass index was associated with reduced overall survival and reduced time to progression in patients with early stage or metastatic HER2-positive breast cancer treated with trastuzumab. Adipocyte-secreted factors may stimulate growth of HER2-positive cancers, blocking the growth inhibitory action of trastuzumab. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811155PMC
March 2013
32 Reads

Situating Nutri-Ethics at the Junction of Nutrigenomics and Nutriproteomics in Postgenomics Medicine.

Curr Pharmacogenomics Person Med 2013 Jun;11(2):162-166

School of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Food has societal, economic, medical and ethical implications, being fundamental for life. It plays an important role also in sports medicine, since a healthy diet is an important part of an athlete's training. Nutrigenomics and nutriproteomics are emerging as a result of a convergence of nutritional, genomics and proteomics knowledge strands in the postgenomics era. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692111311020008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715892PMC
June 2013
7 Reads

Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.

Authors:
Derek So Yann Joly

Curr Pharmacogenomics Person Med 2013 Jun;11(2):98-109

Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada.

In 1996, the US-based biotechnology company Myriad Genetics began offering genetic diagnostic tests for mutations in the genes and , which are linked to hereditary breast and ovarian cancer. Since that time, Myriad has been a forerunner in the field of personalized medicine through the use of effective commercialization strategies which have been emulated by other commercial biotechnology companies. Myriad's strategies include patent acquisition and active enforcement, direct-to-consumer advertising, diversification, and trade secrets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692111311020003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715893PMC
June 2013
6 Reads

Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.

Curr Pharmacogenomics Person Med 2013 Mar;11(1):1-4

Research Group on Complex Collaboration, Faculty of Management, McGill University ; Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada ; Data-Enabled Life Sciences Alliance International (DELSA Global), Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606133PMC
March 2013
29 Reads
3 Citations

Role of Statistical Random-Effects Linear Models in Personalized Medicine.

Curr Pharmacogenomics Person Med 2012 Mar;10(1):22-32

Department of Biostatistics, The University of Kansas Medical Center, Mail Stop 1026, 3901 Rainbow Blvd., Kansas City, KS, 66160, USA.

Some empirical studies and recent developments in pharmacokinetic theory suggest that statistical random-effects linear models are valuable tools that allow describing simultaneously patient populations as a whole and patients as individuals. This remarkable characteristic indicates that these models may be useful in the development of personalized medicine, which aims at finding treatment regimes that are appropriate for particular patients, not just appropriate for the average patient. In fact, published developments show that random-effects linear models may provide a solid theoretical framework for drug dosage individualization in chronic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692111201010022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580802PMC
March 2012
10 Reads

Taking the Kidney Personally: The Quest for Novel Antigens of Idiopathic Membranous Nephropathy through Proteomic Approaches - ?

Curr Pharmacogenomics Person Med 2013 Mar;11(1):5-7

Department of Medicine (Neurology), Brain Sciences Research Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada ; Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1875692111311010002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006827PMC
March 2013
6 Reads

Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective.

Curr Pharmacogenomics Person Med 2012 Dec;10(4):314-321

Section of Pulmonary, Critical Care, Allergy & Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA ; Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

Particulate matter (PM) air pollution exerts significant adverse health effects in global populations, particularly in developing countries with extensive air pollution. Understanding of the mechanisms of PM-induced health effects including the risk for cardiovascular diseases remains limited. In addition to the direct cellular physiological responses such as mitochondrial dysfunction and oxidative stress, PM mediates remarkable dysregulation of gene expression, especially in cardiovascular tissues. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505120PMC
December 2012
12 Reads

Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Curr Pharmacogenomics Person Med 2011 Dec;9(4):299-322

Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

Pharmacogenomics is a field with origins in the study of monogenic variations in drug metabolism in the 1950s. Perhaps because of these historical underpinnings, there has been an intensive investigation of 'hepatic pharmacogenes' such as CYP450s and liver drug metabolism using pharmacogenomics approaches over the past five decades. Surprisingly, kidney pathophysiology, attendant diseases and treatment outcomes have been vastly under-studied and under-theorized despite their central importance in maintenance of health, susceptibility to disease and rational personalized therapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569211798377135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460365PMC
December 2011
13 Reads

Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine?

Curr Pharmacogenomics Person Med 2012 ;10(2):101-105

Department of Family Medicine, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356245PMC
January 2012
6 Reads

Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation.

Curr Pharmacogenomics Person Med 2011 Sep;9(3):191-207

Department of Genetics, Stellenbosch University, Stellenbosch, South Africa.

South Africa, like many other developing countries, stands to benefit from novel diagnostics and drugs developed by pharmacogenomics guidance due to high prevalence of disease burden in the region. This includes both communicable (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569211796957575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228231PMC
September 2011
14 Reads
18 Citations

End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Curr Pharmacogenomics Person Med 2012 Jan;10(1):1-6

Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338471PMC
January 2012
14 Reads

Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Curr Pharmacogenomics Person Med 2011 Jun;9(2):94-101

Department of Medicine, Division of Neurology, University of Toronto, Toronto, Canada.

Tardive dyskinesia (TD) is a serious adverse effect often associated with the first generation antipsychotic medications used in the management of mental health disorders such as schizophrenia. Pharmacogenomics is the study of human genomic variation in relation to individual and population variability in medication response and side effects. Neuropsychiatry is one of the clinical domains in which pharmacogenomic approaches have been extensively studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569211795508448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265539PMC
June 2011
11 Reads

Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

Curr Pharmacogenomics Person Med 2011 Mar;9(1):67-75

Wadhwani Research Center for Biosciences and Bioengineering, Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264661PMC
March 2011
10 Reads

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.

Curr Pharmacogenomics Person Med 2011 Sep;9(3):184-190

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA.

Acquired resistance to Herceptin is a major clinical problem in the treatment of HER2-overexpressing breast cancer. Understanding the molecular mechanisms leading to resistance will allow identification of novel therapeutic targets and predictors of therapeutic response. To this end, up-regulation of anti-apoptotic proteins has been associated with resistance to the HER2-targeted drug lapatinib, but has not yet been linked to Herceptin resistance. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233239PMC
September 2011
7 Reads

Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells.

Curr Pharmacogenomics Person Med 2011 Sep;9(3):229-239

Department of Medicine, Division of Hematology/Oncology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.

Bone marrow transplantation is a form of cell therapy that has been in practice for decades for the treatment of hematological disorders and solid tumors. Immunosuppressive therapy has been a mainstay for treatment, but the severity of the adverse effects has made it an undesirable choice. Mesenchymal stem cells (MSCs), which reside in the vascular regions of the bone marrow, have been shown to serve as cellular support for the hematopoietic stem cell (HSC) niche. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/openurl/content.php?genre=articl
Publisher Site
http://dx.doi.org/10.2174/187569211796957548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164538PMC
September 2011
7 Reads

Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.

Curr Pharmacogenomics Person Med 2011 Mar;9(1):41-66

Department of Molecular Physiology & Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, TN, USA.

Research in human genetics and genetic epidemiology has grown significantly over the previous decade, particularly in the field of pharmacogenomics. Pharmacogenomics presents an opportunity for rapid translation of associated genetic polymorphisms into diagnostic measures or tests to guide therapy as part of a move towards personalized medicine. Expansion in genotyping technology has cleared the way for widespread use of whole-genome genotyping in the effort to identify novel biology and new genetic markers associated with pharmacokinetic and pharmacodynamic endpoints. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569211794728805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163263PMC
March 2011
7 Reads

Nutriproteomics and Proteogenomics: Cultivating Two Novel Hybrid Fields of Personalized Medicine with Added Societal Value.

Curr Pharmacogenomics Person Med 2010 Dec;8(4):240-244

Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569210793368230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052357PMC
December 2010
12 Reads

Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies.

Curr Pharmacogenomics Person Med 2010 Mar;8(1):7-24

Genetics Graduate Program, University of British Columbia, Vancouver, BC, Canada.

Premature loss of telomere repeats underlies the pathologies of inherited bone marrow failure syndromes. Over the past decade, researchers have mapped genetic lesions responsible for the accelerated loss of telomere repeats. Haploinsufficiencies in the catalytic core components of the telomere maintenance enzyme telomerase, as well as genetic defects in telomerase holoenzyme components responsible for enzyme stability, have been linked to hematopoietic failure pathologies. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024291PMC
March 2010
8 Reads

Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.

Curr Pharmacogenomics Person Med 2009 Sep;7(3):215-222

Department of Ophthalmology, Medical College of Georgia, Augusta, GA, USA.

Diabetic retinopathy is a leading cause of blindness in the Western world. However, treatment options for diabetic retinopathy are limited and display poor efficacy with marked patient-to-patient variation in therapeutic outcomes. Discovery of new molecular entities acting on mechanistically novel biological pathways remains as one of the key research priorities in diabetic retinopathy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955420PMC
September 2009
10 Reads

Personalized Medicine Beyond Genomics: New Technologies, Global Health Diplomacy and Anticipatory Governance.

Curr Pharmacogenomics Person Med 2009 Dec;7(4):225-230

Department of Social and Preventive Medicine, Faculty of Medicine, University of Montréal, QC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886025PMC
December 2009
9 Reads

Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?

Curr Pharmacogenomics Person Med 2010 Mar;8(1):25-36

Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.

The euphoria of stem cell therapy has diminished, allowing scientists, clinicians and the general public to seriously re-examine how and what types of stem cells would effectively repair damaged tissue, prevent further tissue damage and/or replace lost cells. Importantly, there is a growing recognition that there are substantial person-to-person differences in the outcome of stem cell therapy. Even though the small molecule pharmaceuticals have long remained a primary focus of the personalized medicine research, individualized or targeted use of stem cells to suit a particular individual could help forecast potential failures of the therapy or identify, early on, the individuals who might benefit from stem cell interventions. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886988PMC
March 2010
5 Reads

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens.

Curr Pharmacogenomics Person Med 2009 Dec;7(4):263-274

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322.

HER2 is over-expressed in approximately 25% to 30% of human metastatic breast cancers, primarily due to gene amplification. There are currently two HER2-targeted therapies approved for clinical use, the monoclonal HER2 antibody trastuzumab and the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. Although both agents show clinical benefit in a subset of patients with metastatic breast cancer, many patients with HER2-over-expressing metastatic breast tumors do not respond to these agents. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840656PMC
December 2009
9 Reads

Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation.

Curr Pharmacogenomics Person Med 2009 Jun;7(2):125

Baylor College of Medicine, Center for Medical Ethics and Health Policy.

Over the last decade there has been vast interest in and focus on the implementation of personalized genomic medicine. Although there is general agreement that personalized genomic medicine involves utilizing genome technology to assess individual risk and ensure the delivery of the "right treatment, for the right patient, at the right time," different categories of stakeholders focus on different aspects of personalized genomic medicine and operationalize it in diverse ways. In order to move toward a clearer, more holistic understanding of the concept, this article begins by identifying and defining three major elements of personalized genomic medicine commonly discussed by stakeholders: molecular medicine, pharmacogenomics, and health information technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569209788653998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809376PMC
June 2009
6 Reads

GENETIC VARIATION IN THE β(2)-ADRENERGIC RECEPTOR: IMPACT ON INTERMEDIATE CARDIOVASCULAR PHENOTYPES.

Curr Pharmacogenomics Person Med 2008 Sep;6(3):160-170

Department of Anesthesiology, Mayo Clinic and Foundation, Rochester, MN, U.S.A.

Genetic variation in drug targets (e.g. receptors) can have pronounced effects on clinical responses to endogenous and exogenous agonists. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651148PMC
September 2008
5 Reads

Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study.

Curr Pharmacogenomics Person Med 2009 Sep;7(3):164-188

Department of Psychiatry and Behavioral Sciences, and Medical Genetics Research Center; SUNY Upstate Medical University; 750 East Adams Street; Syracuse, NY, 13210; USA.

OBJECTIVE: Transcriptomic biomarkers of psychiatric diseases obtained from a query of peripheral tissues that are clinically accessible (e.g., blood cells instead of post-mortem brain tissue) have substantial practical appeal to discern the molecular subtypes of common complex diseases such as major psychosis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083864PMC
September 2009
10 Reads

Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Curr Pharmacogenomics Person Med 2009 Jun;7(2):81-105

Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.

The constitutive androstane receptor (CAR) and the pregnane × receptor (PXR) are activated by a variety of endogenous and exogenous ligands, such as steroid hormones, bile acids, pharmaceuticals, and environmental, dietary, and occupational chemicals. In turn, they induce phase I-III detoxification enzymes and transporters that help eliminate these chemicals. Because many of the chemicals that activate CAR and PXR are environmentally-relevant (dietary and anthropogenic), studies need to address whether these chemicals or mixtures of these chemicals may increase the susceptibility to adverse drug interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187569209788654005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944248PMC
June 2009
10 Reads

Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?

Curr Pharmacogenomics Person Med 2008 Dec;6(4):239-259

Department of Biochemistry & Biophysics, University of Rochester Medical School, Rochester, NY, 14642, USA.

Estrogen hormones play critical roles in the regulation of many tissue functions. The effects of estrogens are primarily mediated by the estrogen receptors (ER) alpha and beta. ERs are ligand-activated transcription factors that regulate a complex array of genomic events that orchestrate cellular growth, differentiation and death. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662734PMC
December 2008
10 Reads

The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies.

Curr Pharmacogenomics Person Med 2008 ;6(3):150-159

Department of Medicine and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

The candidate gene approach to pharmacogenetics is hypothesis driven, and anchored in biological plausibility. Whole genome scanning is hypothesis generating, and it may lead to new biology. While both approaches are important, the scientific community is rapidly reallocating resources toward the latter. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676730PMC
January 2008
8 Reads
  • Page 1 of 1